Trial Details
AuthorisedBasic Information
| Clinical ID | c5103 |
|---|---|
| Identifier | EUCTR2014-001919-39-NL |
| Trial Title | Lengthening Adalimumab Dosing Interval in IBD patients in long termremission, the LADI study |
| Trial URL | Visit Original Page |
Study Information
| Study Results | NULL |
|---|---|
| Conditions | Inflammatory bowel disease;Therapeutic area: Diseases [C] - Immune System Diseases [C20] |
| Interventions | Trade Name: HumiraProduct Name: adalimumabPharmaceutical Form: Solution for injection in pre-filled pen |
Participant Information
| Sponsor | Erasmus MC |
|---|---|
| City | NULL |
| Country/Region | Netherlands |
Enrollment Criteria
| Sex Requirement | NOT SPECIFIED |
|---|---|
| Age Requirement | NULL |
Study Design
| Study Type | Interventional clinical trial of medicinal product |
|---|---|
| Phase | NULL |
Time Information
| Start Date | NULL |
|---|---|
| Primary Completion Date | NULL |
| Completion Date | NULL |